DE60333963D1 - Zytokin Ligand zur Behandlung von Asthma und Atemwegsüberreaktivität - Google Patents

Zytokin Ligand zur Behandlung von Asthma und Atemwegsüberreaktivität

Info

Publication number: DE60333963D1
Authority: DE; Germany
Prior art keywords: seq; amino acid; acid residues; asthma; treatment
Prior art date: 2002-01-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60333963T

Other languages

English (en)

Inventor

Cindy A Sprecher

Joseph L Kuijper

Maria M Dasovich

Francis J Grant

Angela K Hammond

Julia E Novak

Jane A Gross

Stacey R Dillon

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Zymogenetics Inc

Original Assignee

Zymogenetics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-18

Filing date

2003-01-21

Publication date

2010-10-07

2003-01-21 Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc

2010-10-07 Application granted granted Critical

2010-10-07 Publication of DE60333963D1 publication Critical patent/DE60333963D1/de

2023-01-22 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

102000004127 Cytokines Human genes 0.000 title 1
108090000695 Cytokines Proteins 0.000 title 1
208000006673 asthma Diseases 0.000 title 1
230000035874 hyperreactivity Effects 0.000 title 1
239000003446 ligand Substances 0.000 title 1
230000000241 respiratory effect Effects 0.000 title 1
125000000539 amino acid group Chemical group 0.000 abstract 10
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 9
150000001413 amino acids Chemical class 0.000 abstract 2
102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Zoology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Wood Science & Technology (AREA)
Reproductive Health (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Dermatology (AREA)

DE60333963T 2002-01-18 2003-01-21 Zytokin Ligand zur Behandlung von Asthma und Atemwegsüberreaktivität Expired - Lifetime DE60333963D1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US35032502P	2002-01-18	2002-01-18
US37532302P	2002-04-25	2002-04-25
US43531502P	2002-12-19	2002-12-19

Publications (1)

Publication Number	Publication Date
DE60333963D1 true DE60333963D1 (de)	2010-10-07

Family

ID=27407940

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE60333963T Expired - Lifetime DE60333963D1 (de)	2002-01-18	2003-01-21	Zytokin Ligand zur Behandlung von Asthma und Atemwegsüberreaktivität
DE60322188T Expired - Lifetime DE60322188D1 (de)	2002-01-18	2003-01-21	Zytokin (zcytor17-ligand)

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DE60322188T Expired - Lifetime DE60322188D1 (de)	2002-01-18	2003-01-21	Zytokin (zcytor17-ligand)

Country Status (21)

Country	Link
US (12)	US7064186B2 (de)
EP (3)	EP1476541B1 (de)
JP (1)	JP4795641B2 (de)
KR (1)	KR101013401B1 (de)
CN (2)	CN101843895A (de)
AT (3)	ATE478944T1 (de)
AU (2)	AU2003225525B2 (de)
BR (1)	BR0306979A (de)
CA (1)	CA2473686C (de)
CY (1)	CY1112833T1 (de)
DE (2)	DE60333963D1 (de)
DK (3)	DK1961811T3 (de)
ES (3)	ES2310660T3 (de)
IL (3)	IL163066A (de)
NO (1)	NO332266B1 (de)
PL (1)	PL211833B1 (de)
PT (1)	PT2230299E (de)
RU (2)	RU2490276C2 (de)
SI (1)	SI2230299T1 (de)
WO (1)	WO2003060090A2 (de)
ZA (1)	ZA200405695B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2339843T3 (es)	1999-06-02	2010-05-26	Chugai Seiyaku Kabushiki Kaisha	Proteina receptora de hematopoyetina novedosa, nr10.
EP1221482B1 (de)	1999-09-27	2005-12-28	Chugai Seiyaku Kabushiki Kaisha	HäMOPOIETINREZEPTOR-PROTEIN, NR12
US20030096339A1 (en) *	2000-06-26	2003-05-22	Sprecher Cindy A.	Cytokine receptor zcytor17
US9738700B2 (en)	2002-01-18	2017-08-22	Zymogenetics Inc.	ZCYTOR17 heterodimeric cytokine receptor
US7494804B2 (en) *	2002-01-18	2009-02-24	Zymogenetics, Inc.	Polynucleotide encoding cytokine receptor zcytor17 multimer
AU2003225525B2 (en) *	2002-01-18	2008-07-24	Zymogenetics, Inc.	Novel cytokine zcytor17 ligand
WO2005040380A1 (ja) *	2003-10-29	2005-05-06	Bml, Inc.	げっ歯類動物の免疫応答調節蛋白質
JP2007068402A (ja) *	2003-12-26	2007-03-22	Bml Inc	免疫応答調節蛋白質
EP1812469A2 (de) *	2004-11-03	2007-08-01	Boehringer Ingelheim Pharmaceuticals, Inc.	T zellen proteine und ihre kodierenden nukleotidsequenzen
US20060228329A1 (en) *	2005-01-28	2006-10-12	Brady Lowell J	Homogeneous preparations of IL-31
EP1856150A2 (de) *	2005-02-14	2007-11-21	ZymoGenetics, Inc.	Verfahren zur behandlung von durch positive dermale lymphozyten-antigen-zellen hervorgerufene krankheiten
AU2012202218B2 (en) *	2005-02-14	2014-05-22	National Jewish Medical And Research Center	Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells
US20060182743A1 (en) *	2005-02-14	2006-08-17	Janine Bilsborough	Methods of treating skin disorders using an IL-31RA antagonist
EP1869222A4 (de) *	2005-04-15	2010-01-20	Oncomethylome Sciences S A	Methylierungsmarker zur diagnose und behandlung von krebs
ES2561628T3 (es)	2005-05-06	2016-02-29	Zymogenetics, Inc.	Anticuerpos monoclonales IL-31 y métodos de uso
US20130216542A1 (en)	2005-05-06	2013-08-22	Zymogenetics, Inc.	Variable region sequences of il-31 monoclonal antibodies and methods of use
US8101183B2 (en)	2005-05-06	2012-01-24	Zymogentics, Inc.	Variable region sequences of IL-31 monoclonal antibodies
CA2633439A1 (en)	2006-01-10	2007-11-22	Zymogenetics, Inc.	Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
DK2006381T3 (en)	2006-03-31	2016-02-22	Chugai Pharmaceutical Co Ltd	PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
WO2007142325A1 (ja)	2006-06-08	2007-12-13	Chugai Seiyaku Kabushiki Kaisha	炎症性疾患の予防または治療剤
EP2594586B1 (de)	2006-09-01	2014-08-27	ZymoGenetics, Inc.	Monoklonale IL-31-Antikörper und Verfahren zur Verwendung
US8859218B2 (en)	2008-06-13	2014-10-14	Oncohealth Corp.	In situ detection of early stages and late stages HPV infection
CA2672739A1 (en)	2007-01-10	2008-07-17	Zymogenetics, Inc.	Methods of using il-31 to treat airway hyper-responsiveness and asthma
ES2566957T3 (es) *	2007-09-26	2016-04-18	Chugai Seiyaku Kabushiki Kaisha	Región constante de anticuerpo modificado
DK2202245T3 (en)	2007-09-26	2016-11-21	Chugai Pharmaceutical Co Ltd	A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
WO2009052487A2 (en) *	2007-10-18	2009-04-23	University Of South Florida	Method of detecting oncogenesis of hematopoietic cells
MX2010006097A (es)	2007-12-05	2010-08-04	Chugai Pharmaceutical Co Ltd	Agentes terapeuticos para tratar el prurito.
KR20160074019A (ko)	2007-12-05	2016-06-27	추가이 세이야쿠 가부시키가이샤	항ｎｒ１０ 항체 및 그의 이용
PL2796466T3 (pl)	2007-12-07	2018-04-30	Zymogenetics, Inc.	Humanizowane cząsteczki przeciwciała swoiste dla il-31
UA121453C2 (uk) *	2008-04-11	2020-06-10	Чугей Сейяку Кабусікі Кайся	Спосіб одержання фармацевтичної композиції, яка містить антитіло
EP3219812B1 (de)	2008-05-27	2020-09-02	Agilent Technologies, Inc.	Hybridisierungszusammensetzungen und -verfahren
US9303287B2 (en)	2009-02-26	2016-04-05	Dako Denmark A/S	Compositions and methods for RNA hybridization applications
JP2010210772A (ja)	2009-03-13	2010-09-24	Dainippon Screen Mfg Co Ltd	液晶表示装置の製造方法
TWI682995B (zh)	2009-03-19	2020-01-21	日商中外製藥股份有限公司	抗體恆定區域改變體
EP2409991B1 (de)	2009-03-19	2017-05-03	Chugai Seiyaku Kabushiki Kaisha	Variante einer konstanten antikörperregion
US8892184B2 (en)	2010-10-18	2014-11-18	Siemens Medical Solutions Usa, Inc.	Systems and methods for reducing interference in a dual modality imaging system
KR102385507B1 (ko)	2010-11-30	2022-04-12	추가이 세이야쿠 가부시키가이샤	복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
US8790651B2 (en)	2011-07-21	2014-07-29	Zoetis Llc	Interleukin-31 monoclonal antibody
EP2742127B1 (de) *	2011-08-12	2019-10-09	Mello Biotechnology, Inc.	Induzierbare expression in prokaryonten von dem eukaryotischen promotor pol-2
EP2761028A1 (de)	2011-09-30	2014-08-06	Dako Denmark A/S	Hybridisierungszusammensetzungen und -verfahren mit formamid
US11118226B2 (en)	2011-10-21	2021-09-14	Agilent Technologies, Inc.	Hybridization compositions and methods
US10196662B2 (en) *	2012-08-10	2019-02-05	Mello Biotechnology, Inc.	Composition for producing microRNA precursors as drugs for enhancing wound healing and production method of the microRNA precursors
KR101882366B1 (ko)	2013-05-30	2018-07-30	키닉사 파마슈티컬스, 리미티드	온코스타틴 m 수용체 항원 결합 단백질
US10464982B2 (en)	2014-04-23	2019-11-05	Emory University	Compositions of GM-CSF and interleukin fusions for immune modulation and uses related thereto
ES2737723T3 (es)	2014-05-12	2020-01-15	Technion Res & Dev Foundation	Composiciones que comprenden IL-31 y usos de esta
RU2749512C2 (ru)	2015-04-14	2021-06-11	Чугаи Сейяку Кабусики Кайся	Фармацевтическая композиция для профилактики и/или лечения атопического дерматита, включающая антагонист ил-31 в качестве активного ингредиента
KR102514173B1 (ko)	2015-04-14	2023-03-27	추가이 세이야쿠 가부시키가이샤	Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
CN104826100A (zh) *	2015-04-16	2015-08-12	浙江海隆生物科技有限公司	一种猪瘟病毒重组亚单位疫苗的制备方法与应用
DE102015215840B4 (de) *	2015-08-19	2017-03-23	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Multiaperturabbildungsvorrichtung, Abbildungssystem und Verfahren zum Bereitstellen einer Multiaperturabbildungsvorrichtung
US10093731B2 (en)	2017-02-24	2018-10-09	Kindred Biosciences, Inc.	Anti-IL31 antibodies for veterinary use
WO2021100794A1 (ja)	2019-11-20	2021-05-27	中外製薬株式会社	抗体含有製剤
CN111337666B (zh) *	2020-02-12	2021-04-02	山东大学	I-motif重组介导的FRET探针及其原位成像癌细胞表面蛋白质同源二聚化的应用
TWI765431B (zh) *	2020-11-25	2022-05-21	長庚大學	核酸放大系統及其方法
CA3223809A1 (en) *	2021-07-07	2023-01-12	Vib Vzw	Crystal structures of alk and ltk receptor tyrosine kinases and their ligands
WO2025226834A1 (en)	2024-04-23	2025-10-30	Attovia Therapeutics, Inc.	Il31-binding polypeptides and uses thereof

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4054646A (en) *	1973-07-30	1977-10-18	General Electric	Method and apparatus for detection of antibodies and antigens
DK368882A (da)	1981-08-25	1983-02-26	Alan John Kingsman	Expessions vektorer
US4579821A (en)	1981-11-23	1986-04-01	University Patents, Inc.	Control of DNA sequence transcription
US4656134A (en)	1982-01-11	1987-04-07	Board Of Trustees Of Leland Stanford Jr. University	Gene amplification in eukaryotic cells
US4486533A (en)	1982-09-02	1984-12-04	St. Louis University	Filamentous fungi functional replicating extrachromosomal element
US4599311A (en)	1982-08-13	1986-07-08	Kawasaki Glenn H	Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en)	1985-06-26	1990-12-11	Amgen	Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en)	1982-11-24	1986-07-22	The Regents Of The University Of California	Mammalian metallothionein promoter system
US4603044A (en)	1983-01-06	1986-07-29	Technology Unlimited, Inc.	Hepatocyte Directed Vesicle delivery system
US4713339A (en)	1983-01-19	1987-12-15	Genentech, Inc.	Polycistronic expression vector construction
US4661454A (en)	1983-02-28	1987-04-28	Collaborative Research, Inc.	GAL1 yeast promoter linked to non galactokinase gene
US5139936A (en)	1983-02-28	1992-08-18	Collaborative Research, Inc.	Use of the GAL1 yeast promoter
US4650764A (en)	1983-04-12	1987-03-17	Wisconsin Alumni Research Foundation	Helper cell
US4870008A (en)	1983-08-12	1989-09-26	Chiron Corporation	Secretory expression in eukaryotes
US4931373A (en)	1984-05-25	1990-06-05	Zymogenetics, Inc.	Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en)	1985-02-25	1988-08-23	Zymogenetics Inc.	Expression of biologically active PDGF analogs in eucaryotic cells
DE3578435D1 (de)	1984-12-06	1990-08-02	Labofina Sa	Promotoren fuer die expression von fremden genen in hefe, plasmide, die diese promotoren enthalten, sowie deren verwendung zur herstellung von polypeptiden.
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
GR860984B (en)	1985-04-17	1986-08-18	Zymogenetics Inc	Expression of factor vii and ix activities in mammalian cells
US4882279A (en)	1985-10-25	1989-11-21	Phillips Petroleum Company	Site selective genomic modification of yeast of the genus pichia
US4935349A (en)	1986-01-17	1990-06-19	Zymogenetics, Inc.	Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en)	1986-05-15	1986-06-25	Holland I B	Polypeptide
US4980289A (en)	1987-04-27	1990-12-25	Wisconsin Alumni Research Foundation	Promoter deficient retroviral vector
US5063154A (en)	1987-06-24	1991-11-05	Whitehead Institute For Biomedical Research	Pheromone - inducible yeast promoter
DE68926888T2 (de)	1988-01-22	1997-01-09	Zymogenetics Inc	Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US5567584A (en)	1988-01-22	1996-10-22	Zymogenetics, Inc.	Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US4956288A (en)	1988-04-22	1990-09-11	Biogen, Inc.	Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en)	1988-08-05	1991-08-06	Zymogenetics, Inc.	BAR1 secretion signal
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5162228A (en)	1988-12-28	1992-11-10	Takeda Chemical Industries, Ltd.	Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5124263A (en)	1989-01-12	1992-06-23	Wisconsin Alumni Research Foundation	Recombination resistant retroviral helper cell and products produced thereby
US5116964A (en)	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5399346A (en)	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
US6217857B1 (en) *	1989-06-28	2001-04-17	Schering Corporation	Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
US5162222A (en)	1989-07-07	1992-11-10	Guarino Linda A	Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
IL99552A0 (en)	1990-09-28	1992-08-18	Ixsys Inc	Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
JP3202999B2 (ja)	1991-01-31	2001-08-27	協和醗酵工業株式会社	肝移行性リポソーム製剤
US5298418A (en)	1991-09-16	1994-03-29	Boyce Thompson Institute For Plant Research, Inc.	Cell line isolated from larval midgut tissue of Trichoplusia ni
US5641670A (en)	1991-11-05	1997-06-24	Transkaryotic Therapies, Inc.	Protein production and protein delivery
JPH08502646A (ja)	1992-09-14	1996-03-26	ファイザー・インコーポレイテッド	不死化細胞およびその使用
JPH09501055A (ja)	1993-07-30	1997-02-04	ユニバーシティオブメディシンアンドデンティストリーオブニュージャージー	初代リンパ球への効率的遺伝子転移
US6117679A (en)	1994-02-17	2000-09-12	Maxygen, Inc.	Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5492841A (en) *	1994-02-18	1996-02-20	E. I. Du Pont De Nemours And Company	Quaternary ammonium immunogenic conjugates and immunoassay reagents
US5783672A (en)	1994-05-26	1998-07-21	Immunex Corporation	Receptor for oncostatin M
RU2102988C1 (ru) *	1995-02-10	1998-01-27	Зинченко Елена Вениаминовна	Препарат с иммуномодулирующими свойствами
US6074849A (en)	1995-07-19	2000-06-13	Genetics Institute, Inc.	Polynucleotides encoding human CTLA-8 related proteins
AU712650B2 (en)	1995-11-09	1999-11-11	Zymogenetics Inc.	Compositions and methods for producing heterologous polypeptides in pichia methanolica
US6265184B1 (en) *	1995-12-20	2001-07-24	Icos Corporation	Polynucleotides encoding chemokine receptor 88C
US5792850A (en) *	1996-05-23	1998-08-11	Zymogenetics, Inc.	Hematopoietic cytokine receptor
JP2002515746A (ja)	1996-07-17	2002-05-28	ザイモジェネティクス，インコーポレイティド	ピヒア・メタノリカの形質転換
CA2261020C (en)	1996-07-17	2004-06-08	Zymogenetics, Inc.	Preparation of pichia methanolica auxotrophic mutants
CA2273194C (en)	1996-12-03	2011-02-01	Abgenix, Inc.	Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
GB9819420D0 (en)	1998-09-07	1998-10-28	Glaxo Group Ltd	Novel receptor
JP2002543786A (ja) *	1999-05-11	2002-12-24	ザイモジェネティクス，インコーポレイティド	サイトカイン受容体マウスｚｃｙｔｏｒ１０
ES2339843T3 (es)	1999-06-02	2010-05-26	Chugai Seiyaku Kabushiki Kaisha	Proteina receptora de hematopoyetina novedosa, nr10.
AU6531101A (en)	2000-06-02	2001-12-17	Genentech Inc	Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2412211A1 (en)	2000-06-23	2002-01-03	Genetech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
JP2004501628A (ja) *	2000-06-26	2004-01-22	ザイモジェネティクス，インコーポレイティド	サイトカイン受容体ｚｃｙｔｏｒ１７
US20030096339A1 (en)	2000-06-26	2003-05-22	Sprecher Cindy A.	Cytokine receptor zcytor17
EP1354040A2 (de)	2000-07-20	2003-10-22	Genentech, Inc.	Ausgeschiedene und transmembran-polypeptide und nukleinsäuren, welche für diese kodieren
US20030059871A1 (en)	2000-10-06	2003-03-27	Cosman David J.	Hematopoietin receptors HPR1 and HPR2
WO2002077230A1 (fr)	2001-03-26	2002-10-03	Chugai Seiyaku Kabushiki Kaisha	Variants d'epissage nr10
US7494804B2 (en)	2002-01-18	2009-02-24	Zymogenetics, Inc.	Polynucleotide encoding cytokine receptor zcytor17 multimer
AU2003225525B2 (en)	2002-01-18	2008-07-24	Zymogenetics, Inc.	Novel cytokine zcytor17 ligand
EP2110434A1 (de)	2002-02-25	2009-10-21	Genentech, Inc.	Typ-1 Cytokine Rezeptor GLM-R
JP2008534915A (ja) *	2005-01-19	2008-08-28	アイアールエム・リミテッド・ライアビリティ・カンパニー	複数窪み容器の位置決め装置、システム、コンピュータ・プログラム生成物、及び方法
US20060228329A1 (en)	2005-01-28	2006-10-12	Brady Lowell J	Homogeneous preparations of IL-31
US20060182743A1 (en)	2005-02-14	2006-08-17	Janine Bilsborough	Methods of treating skin disorders using an IL-31RA antagonist
EP1856150A2 (de) *	2005-02-14	2007-11-21	ZymoGenetics, Inc.	Verfahren zur behandlung von durch positive dermale lymphozyten-antigen-zellen hervorgerufene krankheiten
US20130216542A1 (en)	2005-05-06	2013-08-22	Zymogenetics, Inc.	Variable region sequences of il-31 monoclonal antibodies and methods of use
ES2561628T3 (es)	2005-05-06	2016-02-29	Zymogenetics, Inc.	Anticuerpos monoclonales IL-31 y métodos de uso
US8101183B2 (en) *	2005-05-06	2012-01-24	Zymogentics, Inc.	Variable region sequences of IL-31 monoclonal antibodies
CA2633439A1 (en)	2006-01-10	2007-11-22	Zymogenetics, Inc.	Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
EP2594586B1 (de)	2006-09-01	2014-08-27	ZymoGenetics, Inc.	Monoklonale IL-31-Antikörper und Verfahren zur Verwendung
CA2672739A1 (en)	2007-01-10	2008-07-17	Zymogenetics, Inc.	Methods of using il-31 to treat airway hyper-responsiveness and asthma
PL2796466T3 (pl)	2007-12-07	2018-04-30	Zymogenetics, Inc.	Humanizowane cząsteczki przeciwciała swoiste dla il-31

2003
- 2003-01-21 AU AU2003225525A patent/AU2003225525B2/en not_active Ceased
- 2003-01-21 ES ES03729693T patent/ES2310660T3/es not_active Expired - Lifetime
- 2003-01-21 US US10/352,554 patent/US7064186B2/en not_active Expired - Lifetime
- 2003-01-21 ES ES08102636T patent/ES2351678T3/es not_active Expired - Lifetime
- 2003-01-21 SI SI200332116T patent/SI2230299T1/sl unknown
- 2003-01-21 EP EP03729693A patent/EP1476541B1/de not_active Expired - Lifetime
- 2003-01-21 RU RU2008118227/10A patent/RU2490276C2/ru not_active IP Right Cessation
- 2003-01-21 WO PCT/US2003/001984 patent/WO2003060090A2/en not_active Ceased
- 2003-01-21 DK DK08102636.1T patent/DK1961811T3/da active
- 2003-01-21 ES ES10168189T patent/ES2377188T3/es not_active Expired - Lifetime
- 2003-01-21 DK DK10168189.8T patent/DK2230299T3/da active
- 2003-01-21 RU RU2004125165/13A patent/RU2360923C2/ru not_active IP Right Cessation
- 2003-01-21 CN CN200910263704A patent/CN101843895A/zh active Pending
- 2003-01-21 PT PT10168189T patent/PT2230299E/pt unknown
- 2003-01-21 BR BR0306979-6A patent/BR0306979A/pt not_active Application Discontinuation
- 2003-01-21 AT AT08102636T patent/ATE478944T1/de active
- 2003-01-21 DE DE60333963T patent/DE60333963D1/de not_active Expired - Lifetime
- 2003-01-21 DE DE60322188T patent/DE60322188D1/de not_active Expired - Lifetime
- 2003-01-21 JP JP2003560177A patent/JP4795641B2/ja not_active Expired - Fee Related
- 2003-01-21 AT AT03729693T patent/ATE401390T1/de active
- 2003-01-21 KR KR1020047011182A patent/KR101013401B1/ko not_active Expired - Fee Related
- 2003-01-21 CA CA2473686A patent/CA2473686C/en not_active Expired - Fee Related
- 2003-01-21 DK DK03729693T patent/DK1476541T3/da active
- 2003-01-21 EP EP08102636A patent/EP1961811B1/de not_active Expired - Lifetime
- 2003-01-21 CN CN03806171A patent/CN100575482C/zh not_active Expired - Fee Related
- 2003-01-21 AT AT10168189T patent/ATE536406T1/de active
- 2003-01-21 PL PL371586A patent/PL211833B1/pl unknown
- 2003-01-21 EP EP10168189A patent/EP2230299B1/de not_active Expired - Lifetime
2004
- 2004-07-15 IL IL163066A patent/IL163066A/en not_active IP Right Cessation
- 2004-07-16 ZA ZA2004/05695A patent/ZA200405695B/en unknown
- 2004-08-17 NO NO20043419A patent/NO332266B1/no not_active IP Right Cessation
2005
- 2005-12-13 US US11/301,764 patent/US7459293B2/en not_active Expired - Fee Related
2006
- 2006-12-12 US US11/609,499 patent/US7425325B2/en not_active Expired - Fee Related
- 2006-12-13 US US11/610,126 patent/US7507795B2/en not_active Expired - Fee Related
- 2006-12-19 US US11/613,091 patent/US7531636B2/en not_active Expired - Fee Related
2008
- 2008-08-18 US US12/193,665 patent/US8013124B2/en not_active Expired - Fee Related
- 2008-10-22 AU AU2008230054A patent/AU2008230054B2/en not_active Ceased
2009
- 2009-01-29 US US12/362,318 patent/US7740834B2/en not_active Expired - Fee Related
2010
- 2010-04-08 US US12/756,959 patent/US8124378B2/en not_active Expired - Fee Related
2011
- 2011-01-04 IL IL210455A patent/IL210455A/en not_active IP Right Cessation
- 2011-01-04 IL IL210454A patent/IL210454A/en not_active IP Right Cessation
2012
- 2012-01-26 US US13/359,049 patent/US8778344B2/en not_active Expired - Fee Related
- 2012-03-06 CY CY20121100217T patent/CY1112833T1/el unknown
2014
- 2014-06-05 US US14/296,488 patent/US9605062B2/en not_active Expired - Fee Related
2017
- 2017-02-10 US US15/429,750 patent/US20180155418A1/en not_active Abandoned
2018
- 2018-09-27 US US16/144,289 patent/US20190338020A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL210454A0 (en)	2011-03-31
PL371586A1 (en)	2005-06-27
IL163066A (en)	2011-08-31
IL210454A (en)	2014-02-27
RU2360923C2 (ru)	2009-07-10
EP1476541A4 (de)	2006-01-11
CA2473686C (en)	2011-09-20
AU2008230054B2 (en)	2012-01-19
ATE401390T1 (de)	2008-08-15
WO2003060090A3 (en)	2004-04-01
EP1476541A2 (de)	2004-11-17
NO332266B1 (no)	2012-08-13
US8124378B2 (en)	2012-02-28
IL210455A (en)	2014-02-27
IL210455A0 (en)	2011-03-31
US8013124B2 (en)	2011-09-06
JP4795641B2 (ja)	2011-10-19
US7459293B2 (en)	2008-12-02
JP2005526494A (ja)	2005-09-08
SI2230299T1 (sl)	2012-07-31
EP2230299B1 (de)	2011-12-07
ES2310660T3 (es)	2009-01-16
RU2008118227A (ru)	2009-11-20
US7064186B2 (en)	2006-06-20
US20130156695A1 (en)	2013-06-20
EP2230299A1 (de)	2010-09-22
KR101013401B1 (ko)	2011-02-14
DE60322188D1 (de)	2008-08-28
AU2008230054A1 (en)	2008-11-13
US20180155418A1 (en)	2018-06-07
BR0306979A (pt)	2004-11-23
KR20040082394A (ko)	2004-09-24
AU2003225525A1 (en)	2003-07-30
EP1961811B1 (de)	2010-08-25
US20070111266A1 (en)	2007-05-17
ES2351678T3 (es)	2011-02-09
US9605062B2 (en)	2017-03-28
US20070077627A1 (en)	2007-04-05
US7507795B2 (en)	2009-03-24
US20060141579A1 (en)	2006-06-29
ATE536406T1 (de)	2011-12-15
US20190338020A1 (en)	2019-11-07
DK1961811T3 (da)	2010-11-08
CN101843895A (zh)	2010-09-29
CY1112833T1 (el)	2016-02-10
US7740834B2 (en)	2010-06-22
WO2003060090A2 (en)	2003-07-24
ES2377188T3 (es)	2012-03-23
EP1961811A1 (de)	2008-08-27
US20110196128A1 (en)	2011-08-11
PL211833B1 (pl)	2012-06-29
RU2004125165A (ru)	2005-04-20
US20090192292A1 (en)	2009-07-30
CA2473686A1 (en)	2003-07-24
DK2230299T3 (da)	2012-03-26
US8778344B2 (en)	2014-07-15
US20030224487A1 (en)	2003-12-04
RU2490276C2 (ru)	2013-08-20
US20150010946A1 (en)	2015-01-08
NO20043419L (no)	2004-10-18
ZA200405695B (en)	2005-03-30
AU2003225525B2 (en)	2008-07-24
CN100575482C (zh)	2009-12-30
US7425325B2 (en)	2008-09-16
US7531636B2 (en)	2009-05-12
EP1476541B1 (de)	2008-07-16
CN1643138A (zh)	2005-07-20
US20090149635A1 (en)	2009-06-11
PT2230299E (pt)	2012-03-02
US20070249020A1 (en)	2007-10-25
ATE478944T1 (de)	2010-09-15
DK1476541T3 (da)	2008-11-03

Publication	Publication Date	Title
DE60333963D1 (de)	2010-10-07	Zytokin Ligand zur Behandlung von Asthma und Atemwegsüberreaktivität
DE60320362D1 (de)	2008-05-29	Verfahren zur Herstellung von Dipeptiden
DE60030769D1 (de)	2006-10-26	Verfahren zur behandlung von entzündungen
ATE333888T1 (de)	2006-08-15	Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
DE60223058D1 (de)	2007-11-29	Zusammensetzungen und verfahren zur behandlung von diabetes
DE602005009856D1 (de)	2008-10-30	Verfahren zur reinigung von fsh
DE602005020165D1 (de)	2010-05-06	Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
ATE450619T1 (de)	2009-12-15	Defructosylierungsverfahren
DE60330146D1 (de)	2009-12-31	Verfahren zur reinigung von fibrinogen
ATE403726T1 (de)	2008-08-15	Cytokin-proteinfamilie
ATE501730T1 (de)	2011-04-15	Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten
EP1734827A4 (de)	2009-01-28	Verfahren und zusammensetzungen zur behandlung von mit anomaler mikrosatellitenexpansion in verbindung stehenden krankheiten
ATE452903T1 (de)	2010-01-15	Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
DE60321443D1 (de)	2008-07-17	Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung
DK2186898T3 (da)	2015-06-22	Blomstrings-induktion
WO2003070770A3 (en)	2003-12-24	Engineered human kunitz-type protease inhibitor
WO2003029290A1 (en)	2003-04-10	Drug transporter and use thereof
DE60312497D1 (de)	2007-04-26	Verwendung von protein maba (fabg1) aus mycobacterium tuberculosis zur herstellung und nachweis von antibiotika
ATE529437T1 (de)	2011-11-15	Verfahren zur sauerstoff-regulierten produktion von recombinanter staphylokinase